ClinicalTrials.gg
RecruitingNCT07825831HEAT-CAREUpdated Sep 23, 2026

AI-Assisted Personalized Heat-Risk Alerts

An interventional study of AI-Assisted Personalized Heat-Risk Alert System and Generic PMD Heat-Health Advisory in Heat-related Illness and Chronic Disease, sponsored by National University of Medical Sciences, Pakistan. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by National University of Medical Sciences, Pakistan · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This two-arm randomized controlled trial will evaluate whether an artificial intelligence-assisted personalized heat-risk alert system reduces heat-related illness symptom burden among adults with chronic conditions. The intervention will integrate prespecified clinical characteristics with the Pakistan Meteorological Department's same-day forecast maximum temperature to classify individual heat-related acute clinical-event risk and deliver personalized alerts through a mobile application. The control group will receive a generic PMD heat-health advisory through the same application.

Read the detailed description

Extreme heat poses increased health risks for adults living with chronic conditions. Conventional heat-health warning systems generally provide population-level advisories and may not account for individual clinical vulnerability. This study will evaluate an artificial intelligence-assisted personalized heat-risk alert system designed to integrate individual clinical characteristics with environmental exposure information.

The trial will enroll 120 adults with hypertension, type 2 diabetes, chronic kidney disease, cardiovascular disease, and/or obesity from the outpatient department of a selected tertiary-care hospital in Gujranwala, Pakistan. Participants will be randomized 1:1 to an intervention or control group and followed for six weeks.

On days when the Pakistan Meteorological Department same-day forecast maximum temperature is ≥36°C, the intervention system will process prespecified clinical characteristics and the temperature forecast through a locked AI Prediction Model. Participants will be classified into low, moderate, or high heat-related acute clinical-event risk categories, with corresponding personalized heat-health messaging. The control group will receive a generic PMD heat-health advisory through the same patient-facing mobile application without AI-based risk stratification or clinical personalization.

The primary outcome is Heat-Related Illness Symptom Score (HRISS) at Week 6. Secondary outcomes include heat-protective behaviors, heat-health knowledge, attitudes and practices, heat-related emergency department visits and hospital admissions, and application engagement. The AI model will be developed and internally validated using a separate historical hospital dataset containing heat-related emergency department visits/admissions and will be locked before intervention delivery.

02

Conditions studied

  • Heat-related Illness
  • Chronic Disease

Browse trials for

Keywords

  • Heat-Health Warning Systems
  • Heat-Related Illness
  • Chronic Diseases
  • Artificial Intelligence
03

In context

Chronic Disease

781 studies on the registry are indexed under Chronic Disease; 144 are open to participants now.

This study's planned enrollment of 120 is below the median of 140 across 582 interventional studies indexed under Chronic Disease.

Browse Chronic Disease studies →

Lead sponsor

National University of Medical Sciences, Pakistan is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older attending the outpatient department of the selected tertiary-care hospital during the recruitment period.
  • Have a documented diagnosis of at least one chronic non-communicable disease associated with increased susceptibility to heat-related illness, including hypertension, type 2 diabetes mellitus, chronic kidney disease, cardiovascular disease, or obesity ( ≥30 kg/m²).
  • Have access to a personal smartphone capable of receiving study heat-risk alert notifications.
  • Be able to read Urdu or English, or have a household member/caregiver available to read and explain study alerts when required.
  • Be willing and able to provide written .
  • Intend to remain within the study catchment area for the duration of the six-week study period to facilitate follow-up.

Exclusion criteria

Exclusion Criteria:

  • Patients requiring immediate emergency treatment or hospital admission at the time of recruitment.
  • Individuals with severe cognitive impairment, dementia, psychotic illness, or another medical condition that limits their ability to understand study procedures or provide .
  • Patients with terminal illness or those receiving palliative care.
  • Individuals with severe visual, hearing, or communication impairments that prevent effective receipt of the study alert intervention and outcome assessment without a reliable caregiver.
  • Pregnant women, because pregnancy has distinct physiological responses to heat exposure and would require separate clinical risk stratification beyond the scope of this study.
  • Participants currently enrolled in another clinical trial or structured behavioral intervention related to heat-health, climate adaptation, or chronic disease self-management.
  • Participants who are unable or unwilling to comply with study procedures or complete the required follow-up assessment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    AI-Assisted Personalized Heat-Risk Alert

    Participants will receive AI-assisted personalized heat-risk alerts through the patient-facing mobile application on days when the Pakistan Meteorological Department's same-day forecast maximum temperature is ≥36°C. A locked AI prediction model will integrate prespecified clinical characteristics and the same-day temperature forecast to classify heat-related acute clinical-event risk as low, moderate, or high. Risk-category-specific heat-health messaging will then be delivered through the application.

    Behavioral: AI-Assisted Personalized Heat-Risk Alert System

  • Active comparator
    Generic PMD Heat-Health Advisory

    Participants will receive a generic Pakistan Meteorological Department heat-health advisory through the same patient-facing mobile application on days when the same-day forecast maximum temperature is ≥36°C. The control condition will not include AI-based risk stratification, individualized risk classification, or disease-specific personalization.

    Behavioral: Generic PMD Heat-Health Advisory

Interventions

  • BehavioralAI-Assisted Personalized Heat-Risk Alert System

    A mobile application-based heat-health alert system that uses a locked AI prediction engine to integrate prespecified individual clinical characteristics with the Pakistan Meteorological Department's same-day forecast maximum temperature (≥36°C) and classify participants into low, moderate, or high heat-related acute clinical-event risk categories. The application delivers corresponding personalized heat-health messages.

  • BehavioralGeneric PMD Heat-Health Advisory

    Generic Pakistan Meteorological Department heat-health advisory delivered through the same patient-facing mobile application when the same-day forecast maximum temperature is ≥36°C, without AI-based risk stratification or individualized clinical personalization.

06

What researchers measure

Primary outcomes

  1. Heat-Related Illness Symptom Score (HRISS)

    The total HRISS score ranges from 0 to 20, based on 10 heat-related illness symptom items assessed for the preceding 7 days; higher scores indicate greater heat-related illness symptom burden. HRISS will be assessed at baseline and Week 6, with the primary analysis comparing Week-6 HRISS between groups after adjustment for baseline HRISS.

    Time frame: Baseline and six weeks after randomization

Secondary outcomes

  1. Heat-Health Protective Behavior Checklist (HPBC)

    The total score on the 10-item Heat-Health Protective Behavior Checklist (HPBC) ranges from 0 to 10, with higher scores indicating greater adoption of heat-protective behaviors. HPBC will be assessed at baseline and Week 6, with the between-group comparison based on the Week-6 score adjusted for baseline.

    Time frame: Baseline and six weeks after randomization

  2. Heat-Health Knowledge, Attitudes and Practices (KAP) Score

    Heat-Health Knowledge, Attitudes and Practices Score, assessed using the 20-item Heat-Health Knowledge, Attitudes and Practices Questionnaire. The total score ranges from 13 to 65, with higher scores indicating better heat-health knowledge, attitudes, and practices. The questionnaire includes 7 knowledge items, 6 attitude items, and 7 practice items.

    Time frame: Baseline and six weeks after randomization

  3. Heat-related hospital admissions

    Number of unplanned hospital admissions attributable to heat-related illness during the six-week intervention period.

    Time frame: From randomization through six weeks

07

Study locations

1 of 1 sites recruiting
  • DHQ Teaching Hospital Gujranwala
    Gujranwala, Punjab Province 52250, Pakistan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant-level data will not be made publicly available because the study involves sensitive clinical and health-related information from the participant population. Data will be retained and managed in accordance with the approved study protocol, institutional requirements, and applicable ethical and privacy requirements. De-identified aggregate findings will be reported in publications and other appropriate dissemination outputs.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2026, 1 month after the start.

Of 318 non-industry interventional studies with no phase under Chronic Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 1 month is below that.

Counting every sponsor, half of 328 studies reached it within 21 months; a quarter within 11 and three quarters within 33.

Chronic Disease covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Sep 17, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Oct 13, 2026
CompletionEst.
Oct 30, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07825831
Lead sponsor
National University of Medical Sciences, Pakistan
Responsible party
Prof. Dr. Shamaila Mohsin, PhD (Head of Department (HoD), Public Health Department, National University of Medical Sciences, Pakistan) — Principal investigator
First posted
Sep 17, 2026
Start date
Sep 1, 2026
Primary completion
Oct 13, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Sep 23, 2026

Study contacts

Mubra Noor, MS Public Health
Contact
mubranoor111@gmail.com
+92- 321-6143378
Shamaila Mohsin, PhD Public Health
principal investigator · Armed Forces Post Graduate Medical Institute, AFPGMI, NUMS, Rawalpindi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion